Want to see GALT full AI Analyst Report?
GALT Stock Chart & Stats
$5.71
-$0.06(-5.00%)
At close: 4:00 PM EST
$5.71
-$0.06(-5.00%)
Day’s Range― - ―
52-Week Range$2.03 - $7.13
Previous CloseN/A
Volume135.57K
Average Volume (3M)964.68K
Market Cap
$274.95M
Enterprise Value$307.34
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$135.72M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume722,875
30 Day Avg. Volume964,676
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory De‑risking: FDA Phase 3 AlignmentClear FDA alignment on Phase 3 endpoints and design materially reduces regulatory uncertainty for belapectin. That durable de‑risking enables a single adequate confirmatory study path to potential approval, strengthens sponsor credibility, and makes the program more attractive to strategic partners and investors over the coming months.
Focused Therapeutic Platform Targeting Galectin‑3A clear scientific focus on galectin‑3 across fibrosis, inflammation and oncology provides a coherent platform strategy. This durable scientific rationale supports multiple development pathways, potential label extensions, and long‑term value creation if clinical proof of mechanism is achieved, beyond single trial outcomes.
Improving Cash Burn And Operating LossesA materially improved cash‑burn trajectory and smaller operating losses indicate stronger cost discipline and operational efficiency. This structural improvement extends runway, reduces short‑term financing pressure, and increases the firm's ability to advance clinical work or negotiate partner terms without immediate dilutive capital raises.
Bears Say
Highly Leveraged Balance SheetDeeply negative equity combined with substantial debt creates persistent financial fragility. Over the medium term this limits flexibility for funding clinical programs, raises the likelihood of dilutive financings or onerous partner terms, and increases solvency risk if clinical timelines or partner discussions slip.
No Operating Revenue And Persistent LossesAbsent product revenue, the company's economics rely entirely on financing and milestones. Persistent multi‑year losses mean ongoing cash requirements to fund trials; structurally this elevates execution risk and dependence on capital markets or partners to sustain development through approval or commercial readouts.
Dependence On Strategic/financial Partners For Phase 3The plan to advance Phase 3 while actively seeking partners signals the company lacks internal resources to fully fund late‑stage development. This structural dependence risks delays or suboptimal collaborations; partner negotiations and timing will materially affect execution and the ultimate commercial pathway.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics (GALT)’s price range in the past 12 months?
Galectin Therapeutics (GALT) lowest stock price was $2.02 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics (GALT)’s market cap?
Galectin Therapeutics (GALT)’s market cap is $274.95M.
When is Galectin Therapeutics (GALT)’s upcoming earnings report date?
Galectin Therapeutics (GALT)’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were Galectin Therapeutics (GALT)’s earnings last quarter?
Galectin Therapeutics (GALT) released its earnings results on May 15, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Galectin Therapeutics (GALT) overvalued?
According to Wall Street analysts Galectin Therapeutics (GALT)’s price is currently Undervalued.
Does Galectin Therapeutics (GALT) pay dividends?
Galectin Therapeutics (GALT) does not currently pay dividends.
What is Galectin Therapeutics (GALT)’s EPS estimate?
Galectin Therapeutics (GALT)’s EPS estimate is -0.09.
How many shares outstanding does Galectin Therapeutics (GALT) have?
Galectin Therapeutics (GALT) has 65,856,895 shares outstanding.
What happened to Galectin Therapeutics (GALT)’s price movement after its last earnings report?
Galectin Therapeutics (GALT) reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.66%.
Which hedge fund is a major shareholder of Galectin Therapeutics (GALT)?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (92.64% Upside)
$11.00 (92.64% Upside)
Blogger Sentiment
Bullish
GALT Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics (GALT)
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(92.64% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
26.04% Insiders
3.90% Mutual Funds
0.02% Other Institutional Investors
63.97% Public Companies and
Individual Investors